Treatment of multi-drug resistant infections using a novel, rapid and customised synthetic phage therapy platform.
Antimicrobial resistance is increasing at an alarming rate globally. Therefore, there is an urgent need to develop alternative, and potentially complementary, therapeutics to combat pathogenic microbes. The use of phage therapeutic methods in a variety of environments is poorly explored. This project aims to explore further the use of phage therapy by establishing an innovative synthetic biology platform to engineer phage therpay candidates within a biofoundry and will leverage the candidate’s skills in one or more of the following areas - microbiology, molecular biology, genetic engineering and laboratory automation. This project will focus on treating multi-drug resistant uropathogenic E. coli (UPEC), which is responsible for one of the most common illnesses - urinary tract infection - and is increasingly associated with antibiotic resistance. Successful outcomes of this project will be peer-reviewed publications in high-impact journals, intellectual property and the chance to make a positive difference in the lives of people chronically infected by UPEC pathogens.
Australian and international applicants welcome. First class Honours/ Masters in a related discipline such as Microbiology, Molecular Biology, Bioengineering, or Virology required.